加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.993
+US$0.0096 · +0.98%
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
前收盘价
US$0.993
+US$0.0096 · +0.98%
盘中时间采用ET。市场数据可能有所延迟。
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
日内区间
当前US$0.993
52周区间
当前US$0.993
盘中时间采用ET。市场数据可能有所延迟。
Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization. Another significant compound is CTX-471, an IgG4 monoclonal antibody that functions as an activator of CD137. Furthermore, their developmental pipeline features CTX-8371, a bispecific inhibitor that targets both PD-1 and PD-L1. The company was established in 2014 and operates from its headquarters in Boston, Massachusetts.
日内区间
当前US$0.993
52周区间
当前US$0.993
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | 85万 USD | — | — | — |
| 销货成本 | 147.2万 USD | — | — | — | — |
| 毛利 | −147.2万 USD | 85万 USD | — | — | — |
| 研究与开发 | 5596.9万 USD | 4234.2万 USD | 3812万 USD | 2999.7万 USD | 2033.7万 USD |
| 销售、一般及管理费用 | 1687万 USD | 1513.3万 USD | 1224.3万 USD | 1165.8万 USD | 1092.7万 USD |
| 营业费用 | 7136.7万 USD | 5747.5万 USD | 5036.3万 USD | 4165.5万 USD | 8188.2万 USD |
| 利息收入 | 635万 USD | 730万 USD | 790万 USD | 236万 USD | 2.9万 USD |
| 利息支出 | — | — | — | 236万 USD | 37万 USD |
| 折旧和摊销 | 147.2万 USD | 175.3万 USD | 189万 USD | 190.4万 USD | 162.4万 USD |
| 营业利润 | −7283.9万 USD | −5662.5万 USD | −5036.3万 USD | −4165.5万 USD | −8188.2万 USD |
| 净利润 | −6648.9万 USD | −4937.5万 USD | −4249.4万 USD | −3922.5万 USD | −8218.1万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
